The prevalence of metabolically healthy obesity: A systematic review and critical evaluation of the definitions used

Obesity Reviews

Volumn 15, Issue 10, 2014, Pages 781-790

  Rey Lopez J P ^a   de Rezende, L F ^a,b   Pastor Valero, M ^c,d   Tess, B H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Centro de Estudos do Laboratorio de Aptidão Fisica de São Caetano do Sul CELAFISCS   (Brazil)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Epidemiology; Obesity phenotype; Prevalence

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LEUKOCYTE COUNT; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; REVIEW; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY COMPOSITION; CLASSIFICATION; HEALTH BEHAVIOR; METABOLISM; PHYSIOLOGY; PROSPECTIVE STUDY;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; HEALTH BEHAVIOR; HUMANS; OBESITY; PREVALENCE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84924292243     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12198     Document Type: Review

References (48)

1. Finucane MM, Stevens GA, Cowan MJ etal. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557-567.
2. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2013; 9: 13-27.
3. Whitlock G, Lewington S, Sherliker P. Body-mass index and cause-specific mortality in 900, 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
4. Blüher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 2012; 19: 341-346.
5. Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord 2013; 14: 219-227.
6. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013; 159: 758-769.
7. Stefan N, Haring HU, Hu FB, Shulze MB. Metabolically healthy obesity: epidemiology, mechanisms and clinical implications. Lancet Diabetes Endocrinol 2013; 1: 152-162.
8. Camhi SM, Waring ME, Sisson SB, Hayman LL, Must A. Physical activity and screen time in metabolically healthy obese phenotypes in adolescents and adults. J Obes 2013; 2013: 984613.
9. Appleton SL, Seaborn CJ, Visvanathan R etal. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013; 36: 2388-2394.
10. Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care 2009; 32: 2297-2299.
11. Calori G, Lattuada G, Piemonti L etal. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011; 34: 210-215.
12. Boyle MH. Guidelines for evaluating prevalence studies. Evid Based Mental Health 1998; 1: 37-39.
13. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97: 2482-2488.
14. Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 2010; 64: 1043-1051.
15. Soriguer F, Gutiérrez-Repiso C, Rubio-Martín E etal. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab 2013; 98: 2318-2325.
16. Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236.
17. Choi KM, Cho HJ, Choi HY etal. Higher mortality in metabolically obese normal-weight people than in metabolically healthy obese subjects in elderly Koreans. Clin Endocrinol 2013; 79: 364-370.
18. Doumatey AP, Bentley AR, Zhou J, Huang H, Adeyemo A, Rotimi CN. Paradoxical hyperadiponectinemia is associated with the Metabolically Healthy Obese (MHO) phenotype in African Americans. J Endocrinol Metab 2012; 2: 51-65.
19. Durward CM, Hartman TJ, Nickols-Richardson SM. All-cause mortality risk of metabolically healthy obese individuals in NHANES III. J Obes 2012; 2012: 460321.
20. Eglit T, Ringmets I, Lember M. Obesity, High-Molecular-Weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia. PLoS ONE 2013; 8: e73273.
21. Geetha L, Deepa M, Anjana RM, Mohan V. Prevalence and clinical profile of metabolic obesity and phenotypic obesity in Asian Indians. J Diabetes Sci Technol 2011; 5: 439-446.
22. Hamer M, Batty GD, Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the English longitudinal study of ageing. Mol Psychiatry 2012; 17: 940-945.
23. Lee K. Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors. Asia Pac J Clin Nutr 2009; 18: 280-284.
24. Lee SK, Kim SH, Cho GY etal. Obesity phenotype and incident hypertension: a prospective community-based cohort study. J Hypertens 2013; 31: 145-151.
25. Lopez-Garcia E, Guallar-Castillon P, Leon-Muñoz L, Rodriguez-Artalejo F. Prevalence and determinants of metabolically healthy obesity in Spain. Atherosclerosis 2013; 231: 152-157.
26. Manu P, Ionescu-Tirgoviste C, Tsang J, Napolitano BA, Lesser ML, Correll CU. Dysmetabolic signals in 'Metabolically Healthy' obesity. Obes Res Clin Pract 2012; 6: e9-e20.
27. Phillips CM, Dillon C, Harrington JM etal. Defining metabolically healthy obesity: role of dietary and lifestyle factors. PLoS ONE 2013; 8: e76188.
28. Ul-Haq Z, Mackay DF, Fenwick E, Pell JP. Impact of metabolic comorbidity on the association between body mass index and health-related quality of life: a Scotland-wide cross-sectional study of 5, 608 participants. BMC Public Health 2012; 12: 143.
29. Gomez-Huelgas R, Narankiewicz D, Villalobos A etal. Prevalence of metabolically discordant phenotypes in a Mediterranean population - The IMAP study. Endocr Pract 2013; 19: 758-768.
30. Hwang LC, Bai CH, Sun CA, Chen CJ. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. Asia Pac J Clin Nutr 2012; 21: 227-233.
31. Hankinson AL, Daviglus ML, Van Horn L etal. Diet composition and activity level of at risk and metabolically healthy obese American adults. Obesity (Silver Spring) 2013; 21: 637-643.
32. Hong HC, Lee JS, Choi HY etal. Liver enzymes and vitamin D levels in metabolically healthy but obese individuals: Korean National Health and Nutrition Examination Survey. Metabolism 2013; 62: 1305-1312.
33. Lind L, Siegbahn A, Ingelsson E, Sundström J, Arnlöv J. A detailed cardiovascular characterization of obesity without the metabolic syndrome. Arterioscler Thromb Vasc Biol 2011; 31: e27-e34.
34. van der A DL, Nooyens AC, van Duijnhoven FJ, Verschuren MM, Boer JM. All-cause mortality risk of metabolically healthy abdominal obese individuals: The EPIC-MORGEN study. Obesity (Silver Spring) 2014; 22: 557-564.
35. Wildman RP, Muntner P, Reynolds K. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168: 1617-1624.
36. Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO). Diabetes Metab 2004; 30: 569-572.
37. Meigs JB, Wilson PW, Fox CS etal. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912.
38. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C, O'Shea DB. Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 2009; 17: 601-605.
39. Aguilar-Salinas CA, Garcia EG, Robles L etal. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008; 93: 4075-4079.
40. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
41. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
42. Hinnouho GM, Czernichow S, Dugravot A, Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care 2013; 36: 2294-2300.
43. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol 2007; 17: 643-653.
44. Vague J. The degree of masculine differentiation: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculus disease. Am J Clin Nutr 1956; 4: 20-34.
45. Kvist H, Chowdhury B, Grangard U, Tylen U, Sjöström L. Total and visceral adipose tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr 1988; 48: 1351-1361.
46. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359-404.
47. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab 2013; 98: E1610-E1619.
48. Hocking S, Samocha-Bonet D, Milner KL, Greenfield JR, Chisholm DJ. Adiposity and insulin resistance in humans: the role of different tissue and cellular lipid depots. Endocr Rev 2013; 34: 463-500.